Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 with chemoradiotherapy in recurrent or metastatic esophageal squamous cell carcinoma
ChiCTR2000031544Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of erfonrilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: objective response rate, duration of response and 1 more. Started Apr 2019; status: recruiting.
02
Drugs
erfonrilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000031544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031544.